Skip to main content
Erschienen in: Die Nephrologie 6/2019

02.10.2019 | Akutes Nierenversagen | Leitthema

Akutes pulmorenales Syndrom auf der Intensivstation

Rationale Diagnostik und Therapie

verfasst von: P. Enghard, C. Erley, A. Schreiber

Erschienen in: Die Nephrologie | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das akute pulmorenale Syndrom (PRS) besteht in der Kombination einer pulmonalen Hämorrhagie mit einem akuten Nierenversagen in Folge einer gemeinsamen immunologischen Ursache. Das PRS stellt ein lebensbedrohliches Krankheitsbild dar, weshalb diese Patienten häufig auf der Intensivstation diagnostiziert und behandelt werden müssen. Die Frage eines möglichen PRS stellt Intensivmediziner regelhaft vor verschiedene Herausforderungen, wie die der Differenzialdiagnose zwischen Infekt und aktivem PRS und die Frage der Behandlung bei noch unsicherer Diagnose. Die häufigste Ursache eines PRS ist die ANCA(antineutrophile zytoplasmatische Antikörper)-assoziierte Vaskulitis; seltenere Ursachen sind u. a. Anti-GBM(glomeruläre Basalmembran)-Erkrankung und der systemische Lupus erythematodes. Daneben bietet die internistische Intensivmedizin viele andere Krankheitsbilder, die diese Kombination von Organmanifestationen imitieren können und abgegrenzt werden müssen. Zusammengenommen stellt das PRS ein wichtiges Krankheitsbild und eine wichtige Differenzialdiagnose in der internistischen Intensivmedizin dar.
Literatur
1.
Zurück zum Zitat Cruz BA et al (2003) Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology 42:1183–1188PubMed Cruz BA et al (2003) Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology 42:1183–1188PubMed
2.
Zurück zum Zitat Gallagher H, Kwan JTC, Jayne DRW (2002) Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 39:42–47PubMed Gallagher H, Kwan JTC, Jayne DRW (2002) Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 39:42–47PubMed
3.
Zurück zum Zitat Kimmoun A et al (2016) Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study. Crit Care 20:27PubMedPubMedCentral Kimmoun A et al (2016) Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study. Crit Care 20:27PubMedPubMedCentral
4.
Zurück zum Zitat Holguin F, Ramadan B, Gal AA, Roman J (2008) Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci 336:321–326PubMedPubMedCentral Holguin F, Ramadan B, Gal AA, Roman J (2008) Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci 336:321–326PubMedPubMedCentral
6.
Zurück zum Zitat Demiselle J et al (2017) Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study. Ann Intensive Care 7:39PubMedPubMedCentral Demiselle J et al (2017) Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study. Ann Intensive Care 7:39PubMedPubMedCentral
7.
Zurück zum Zitat Quadrelli S et al (2017) Immune diffuse alveolar hemorrhage: Clinical presentation and outcome. Respir Med 129:59–62PubMed Quadrelli S et al (2017) Immune diffuse alveolar hemorrhage: Clinical presentation and outcome. Respir Med 129:59–62PubMed
8.
Zurück zum Zitat Collard HR, Schwarz MI (2004) Diffuse alveolar hemorrhage. Clin Chest Med 25:583–592PubMed Collard HR, Schwarz MI (2004) Diffuse alveolar hemorrhage. Clin Chest Med 25:583–592PubMed
9.
Zurück zum Zitat Bowley NB, Steiner RE, Chin WS (1979) The chest X‑ray in antiglomerular basement membrane antibody disease (Goodpasture’s syndrome). Clin Radiol 30:419–429PubMed Bowley NB, Steiner RE, Chin WS (1979) The chest X‑ray in antiglomerular basement membrane antibody disease (Goodpasture’s syndrome). Clin Radiol 30:419–429PubMed
10.
Zurück zum Zitat Feragalli B et al (2016) The lung in systemic vasculitis: radiological patterns and differential diagnosis. Br J Radiol 89:20150992PubMedPubMedCentral Feragalli B et al (2016) The lung in systemic vasculitis: radiological patterns and differential diagnosis. Br J Radiol 89:20150992PubMedPubMedCentral
11.
Zurück zum Zitat Cavanaugh C, Perazella MA (2019) Urine sediment examination in the diagnosis and management of kidney disease: core curriculum 2019. Am J Kidney Dis 73:258–272PubMed Cavanaugh C, Perazella MA (2019) Urine sediment examination in the diagnosis and management of kidney disease: core curriculum 2019. Am J Kidney Dis 73:258–272PubMed
12.
Zurück zum Zitat Bossuyt X et al (2017) Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13:683–692PubMed Bossuyt X et al (2017) Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13:683–692PubMed
13.
Zurück zum Zitat Agmon-Levin N et al (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23PubMed Agmon-Levin N et al (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23PubMed
14.
Zurück zum Zitat Conrad K, Röber N, Andrade LEC, Mahler M (2017) The Clinical Relevance of Anti-DFS70 Autoantibodies. Clin Rev Allergy Immunol 52:202–216PubMed Conrad K, Röber N, Andrade LEC, Mahler M (2017) The Clinical Relevance of Anti-DFS70 Autoantibodies. Clin Rev Allergy Immunol 52:202–216PubMed
15.
Zurück zum Zitat Rutgers A et al (2005) Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46:253–262PubMed Rutgers A et al (2005) Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46:253–262PubMed
16.
Zurück zum Zitat McAdoo SP et al (2017) Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92:693–702PubMedPubMedCentral McAdoo SP et al (2017) Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92:693–702PubMedPubMedCentral
17.
Zurück zum Zitat Yates M et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594PubMed Yates M et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594PubMed
18.
Zurück zum Zitat Schirmer JH et al (2017) S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 76:77–104PubMed Schirmer JH et al (2017) S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 76:77–104PubMed
19.
Zurück zum Zitat Bjørneklett R, Sriskandarajah S, Bostad L (2016) Prognostic value of histologic classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 11:2159–2167PubMedPubMedCentral Bjørneklett R, Sriskandarajah S, Bostad L (2016) Prognostic value of histologic classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 11:2159–2167PubMedPubMedCentral
20.
Zurück zum Zitat Rose T et al (2017) Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology 56:1618–1626PubMed Rose T et al (2017) Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology 56:1618–1626PubMed
21.
Zurück zum Zitat Costa e SVT et al (2013) Nephrology referral and outcomes in critically ill acute kidney injury patients. PLoS ONE 8:e70482 Costa e SVT et al (2013) Nephrology referral and outcomes in critically ill acute kidney injury patients. PLoS ONE 8:e70482
22.
Zurück zum Zitat Herrmann K, Schinke S, Csernok E, Moosig F, Holle JU (2015) Diagnostic value of procalcitonin in ANCA-associated Vasculitis (AAV) to differentiate between disease activity, infection and drug hypersensitivity. Open Rheumatol J 9:71–76PubMedPubMedCentral Herrmann K, Schinke S, Csernok E, Moosig F, Holle JU (2015) Diagnostic value of procalcitonin in ANCA-associated Vasculitis (AAV) to differentiate between disease activity, infection and drug hypersensitivity. Open Rheumatol J 9:71–76PubMedPubMedCentral
23.
Zurück zum Zitat Eberhard OK et al (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40:1250–1256PubMed Eberhard OK et al (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40:1250–1256PubMed
24.
Zurück zum Zitat Specks U et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417–427PubMedPubMedCentral Specks U et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417–427PubMedPubMedCentral
25.
Zurück zum Zitat Jones RB et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2‑year results of a randomised trial. Ann Rheum Dis 74:1178–1182PubMed Jones RB et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2‑year results of a randomised trial. Ann Rheum Dis 74:1178–1182PubMed
26.
Zurück zum Zitat Geetha D et al (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26:976–985PubMed Geetha D et al (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26:976–985PubMed
27.
Zurück zum Zitat Appel GB et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112PubMedPubMedCentral Appel GB et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112PubMedPubMedCentral
28.
Zurück zum Zitat Beck L et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 62:403–441PubMed Beck L et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 62:403–441PubMed
29.
Zurück zum Zitat Mohammad AJ et al (2017) Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 44:1468–1475PubMed Mohammad AJ et al (2017) Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 44:1468–1475PubMed
30.
Zurück zum Zitat Kronbichler A et al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440–1447PubMed Kronbichler A et al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440–1447PubMed
31.
Zurück zum Zitat Walsh M et al (2013) Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84:397–402PubMed Walsh M et al (2013) Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84:397–402PubMed
32.
Zurück zum Zitat Cui Z et al (2011) Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine 90:303–311PubMed Cui Z et al (2011) Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine 90:303–311PubMed
33.
Zurück zum Zitat Johnson JP et al (1985) Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine 64:219–227PubMed Johnson JP et al (1985) Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine 64:219–227PubMed
34.
Zurück zum Zitat Kronbichler A, Brezina B, Quintana LF, Jayne DRW (2016) Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 15:38–49PubMed Kronbichler A, Brezina B, Quintana LF, Jayne DRW (2016) Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 15:38–49PubMed
36.
Zurück zum Zitat Jayne DR et al (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMed Jayne DR et al (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMed
38.
Zurück zum Zitat Venkatesh B et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797–808PubMed Venkatesh B et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797–808PubMed
39.
Zurück zum Zitat Annane D et al (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378:809–818PubMed Annane D et al (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378:809–818PubMed
40.
Zurück zum Zitat Keh D et al (2016) Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 316:1775–1785PubMed Keh D et al (2016) Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 316:1775–1785PubMed
41.
Zurück zum Zitat Knaup H et al (2018) Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 22:285PubMedPubMedCentral Knaup H et al (2018) Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 22:285PubMedPubMedCentral
42.
Zurück zum Zitat Guérin C et al (2013) Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 368:2159–2168PubMed Guérin C et al (2013) Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 368:2159–2168PubMed
43.
Zurück zum Zitat Delvino P et al (2019) The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. Rheumatol Int 39:367–375PubMed Delvino P et al (2019) The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. Rheumatol Int 39:367–375PubMed
44.
Zurück zum Zitat Patel JJ, Lipchik RJ (2014) Systemic lupus-induced diffuse alveolar hemorrhage treated with extracorporeal membrane oxygenation: a case report and review of the literature. J Intensive Care Med 29:104–109PubMed Patel JJ, Lipchik RJ (2014) Systemic lupus-induced diffuse alveolar hemorrhage treated with extracorporeal membrane oxygenation: a case report and review of the literature. J Intensive Care Med 29:104–109PubMed
Metadaten
Titel
Akutes pulmorenales Syndrom auf der Intensivstation
Rationale Diagnostik und Therapie
verfasst von
P. Enghard
C. Erley
A. Schreiber
Publikationsdatum
02.10.2019

Weitere Artikel der Ausgabe 6/2019

Die Nephrologie 6/2019 Zur Ausgabe

Einführung zum Thema

Intensivmedizin

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.